Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Salivary Gland Function in Head and Neck Cancer
NCT03578432Phase 1Terminated
- Sponsor
- University of Arizona
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in Salivary gland disorders and xerostomia, sponsored by University of Arizona. Primary endpoint: Percent recovery of salivary gland function. Started May 2018; status: terminated.
02
Drugs
everolimus
03
Conditions
Salivary gland disordersxerostomia
Beyond the preview
Go deeper on NCT03578432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578432.